The report by Aycock and Luther in this issue of The Journal1 is a significant contribution to the study of the treatment of epidemic poliomyelitis. The main indication for treatment in this disease is the prevention of paralysis, which is due to the action of the poliomyelitic virus on the nerve cells that preside over movement and nutrition of voluntary muscles. Fortunately there is a period in the evolution of the attack of poliomyelitis during which it may be possible to neutralize the virus before it can develop its maximum destructive effects on the motor nerve cells. This is the preparalytic stage of the disease and there seems to be no question that poliomyelitis can be recognized in this stage. At any rate the report by Aycock and Luther marks a definite advance in the treatment of poliomyelitis in the early stages, because it is based on a series
CONVALESCENT SERUM IN EPIDEMIC POLIOMYELITIS. JAMA. 1928;91(6):398. doi:10.1001/jama.1928.02700060032012
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.